Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaginal Estradiol vs Oral Beta-3 Agonist for Treatment of Overactive Bladder Syndrome
NCT05221021Phase 4Recruiting
- Sponsor
- Walter Reed National Military Medical Center
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of estradiol topical and mirabegron in overactive bladder syndrome (OAB) (2 arms), sponsored by Walter Reed National Military Medical Center. Primary endpoint: Overactive Bladder Questionnaire Short Form Symptom Bother Score at 12 weeks. Started Oct 2022; status: recruiting.
02
Drugs
estradiol topicalmirabegron
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT05221021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221021.